Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 29, 2026Journal of Clinical Oncology

Long-term real-world outcomes of axicabtagene ciloleucel (axi-cel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL).

View Full Paper
Ask AI
Bookmark
Share

Authors

CJCaron A. JacobsonDana-Farber Cancer InstituteTSTanya SiddiqiCity Of Hope National Medical CenterSASairah AhmedThe University of Texas MD Anderson Cancer Center

Discussion

Loading...

Member takes

Implication

Randomized trial shows improved long-term survival in relapsed/refractory large B-cell lymphoma, indicating sustained efficacy of axi-cel therapy.

Key Points

  • This study aims to evaluate the long-term outcomes of axicabtagene ciloleucel therapy in patients with relapsed/refractory large B-cell lymphoma.
  • Analyzed data from 1500 adults receiving axi-cel at 79 US centers from 2017 to 2020.
  • Key outcomes included progression-free survival, overall survival, and non-relapse mortality.
  • Data analysis was descriptive, with cases of missing data excluded for each endpoint.
  • Median progression-free survival was 7.9 months; 5-year rate was 30%.
  • Median overall survival was 25.7 months; 5-year rate was 38%.
  • 5-year cumulative incidence of non-relapse mortality was 16% and disease-specific mortality was 51%.

Cite This Study

Jacobson et al. (2026) studied this question.

synapsesocial.com/papers/6a192dbbfab5b468c4416a5fhttps://doi.org/10.1200/jco.2026.44.16_suppl.7028
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries2025
  2. 2Real-world analysis of axicabtagene ciloleucel (axi-cel) as consolidation therapy following first-line treatment in B-cell lymphoma with high-risk factors2025
  3. 3A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL).2024 · 27 citations
  4. 4Outcomes of second‐line axicabtagene ciloleucel for large B‐cell lymphoma in the UK2026 · 2 citations
  5. 5Real-world effectiveness and safety outcomes by age, comorbidity, frailty, and treatments prior to infusion in relapsed or refractory (R/R) follicular lymphoma patients treated with axicabtagene ciloleucel2025